|
- eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus . . .
CTLA-4 combinations Data from the first-in-human phase 1 2 study (NCT03530397) showed encouraging antitumor activity and acceptable tolerability with 1L volrustomig plus carboplatin pemetrexed (CP) in NSCLC, particularly in pts with PD-L1 TC ,1% The phase 3, two-arm, parallel-group, randomized, multicenter, open-label eVOLVE-Lung02 study
- ClinicalTrials. gov
Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information Search for terms
- Real-world multicentre cohort of first-line pembrolizumab alone or in . . .
Pembrolizumab alone (IO-mono) or in combination with platinum-based chemotherapy (CT-IO) is first-line standard of care for advanced non-small cell lung cancer (NSCLC) patients with PD-L1 ≥ 50% This retrospective multicentre study assessed real-world use and efficacy of both strategies
- Program Guide – ASCO Meeting Program Guide
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%
- Treatment Patterns and Outcomes After Chemotherapy and Anti–PD-(L)1 in . . .
Lung cancer is the third most common cancer and the leading cause of cancer deaths in the US, with an estimated 234 580 new diagnoses and 125 070 deaths expected in 2024 1 Non–small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of lung cancer diagnoses in the US 2 The programmed cell death 1 protein (PD-1) pathway plays a
- Real-World Safety and Outcome of First-Line Pembrolizumab . . . - MDPI
Results from the phase III Keynote-024 clinical trial established pembrolizumab monotherapy as the first-line standard of care for patients with metastatic NSCLC who have PD-L1 expression ≥ 50%, EGFR, and ALK wild-type tumors
- HSR23-117: First-Line (1L) Systemic Therapy in Patients (pts . . . - JNCCN
Background: Current US regulatory approved and recommended 1L therapy for aNSCLC without actionable molecular biomarkers incorporates programmed death 1 (PD-1) or PD-ligand 1 (PD-L1) inhibitor immunotherapy, with or without platinum-based chemotherapy depending on tumor histology and PD-L1 expression Our objective was to describe 1L treatment
- First-line treatment with camrelizumab plus famitinib in advanced or . . .
Here, we evaluated the eficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase inhibitor) as a first- line treatment for advanced or metastatic NSCLC patients with a programmed death ligand- 1 (PD- L1) tumor proportion score (TPS) of ≥1%, in an open- label, multicenter, phase 2 basket trial
|
|
|